Safi Gets $4.7M Award Extension for Manufactured Blood

Storage is part of the medicine when the product is blood. Safi Biotherapeutics, the Cambridge, Massachusetts company growing human red blood cells from stem cells, is building its development program around the practical distance between making those cells and having them available for a transfusion.

Safi's November 3, 2026 announcement adds a $4.7M non-dilutive government award extension to that work. The funding comes through the Medical Technology Enterprise Consortium, or MTEC, from the U.S. Defense Health Program's Combat Casualty Care portfolio. It supports final work toward a planned 2027 Investigational New Drug submission for acute blood loss and the company's first clinical trial.

The operating significance reaches beyond a financing headline. A manufactured blood product has to travel through production, preservation and clinical evaluation before a hospital or military medical team can depend on it. Safi is financing that journey while developing a cryopreserved formulation, with human clinical performance still ahead of the company.

What the $4.7M extension funds

The latest award extends government-backed development rather than introducing a new equity round. Safi reports that the extension brings its cumulative non-dilutive government funding above $27M, including this award. That figure describes government support; the company separately announced a $5M Seed round led by J2 Ventures in September 2024.

Those sources of capital have supported a company whose prospective customers need evidence long before they can buy a finished product. Government funding can carry a defined medical-development objective across that period. For Safi, the current assignment is IND-enabling work for acute blood loss, alongside continued development of readily transfusable, cryopreserved manufactured red blood cells, or mRBCs.

An IND is a request for FDA authorization to administer an investigational product to people. Safi's planned filing and trial therefore sit at a specific point in development: preparing to collect human evidence. The announcement supplies a funding amount and intended milestone, without a disclosed trial protocol, commercial price or established human efficacy result.

Production has to survive the transfer

Safi's manufacturing work has already moved between organizations. In January 2026, Safi and ARMI | BioFabUSA announced the technical transfer of a 10-liter mRBC production system. Safi now says a single bioreactor can produce more than a transfusable unit, with economics the company considers viable. The public announcement does not provide an independently audited unit-cost comparison.

That transfer gives the story a different scale from an isolated laboratory result. A process intended for clinical supply must be usable by the people and organization responsible for manufacturing it. The work includes making the process repeatable and preserving the characteristics that justified developing the cells in the first place. Production volume becomes useful when the resulting material can support the next development step.

Safi's current official team includes CEO and co-founder Doug McConnell, co-founder Jon Mogford, CTO Rob Thomas, COO Kyle Meetze and Scientific Lead Katie Glen. Mogford's biography traces his involvement to DARPA's 2008–2012 Blood Pharming program; Thomas brings cell-process development and manufacturing experience. The team's history puts the award inside a longer effort to turn blood-cell research into a product an outside manufacturing partner can prepare for clinical work.

Preservation changes where supply can reach

MTEC's project account of Safi's work identifies limited storage duration and cold-chain logistics as obstacles to battlefield blood availability. Its framing is deliberately about supplementing supply for military trauma care and civilian emergencies. A usable inventory needs to remain usable while demand and location change.

Safi is pursuing refrigerated, cryopreserved and freeze-dried formulations at different stages of development. Its March 2026 collaboration with DesiCorp focuses on freeze-drying and reconstitution, drawing together cell manufacturing and preservation expertise. A portable, shelf-stable formulation remains a development objective; the collaboration announcement establishes the work, rather than a finished product that can already be stockpiled without refrigeration.

The commercial consequence is unusually physical. Improving how a cell survives storage could change the settings a future product can serve, but each formulation also creates its own development assignment. Hospital storage and far-forward military use can share a manufacturing origin while placing different demands on the product that leaves it. Safi's latest award keeps that preservation work connected to the approach toward clinical use.

The clinical question follows the manufacturing question

Manufactured red cells also belong to a broader research field. NHS Blood and Transplant describes its RESTORE study as a Phase I crossover trial comparing the recovery and survival of a mini-dose of laboratory-grown cells with donated red cells in healthy volunteers. Its study page says recruitment has closed. That separate program illustrates the kind of biological question researchers must investigate; it supplies no clinical result for Safi.

Safi has also been developing applications for chronic transfusion in sickle cell disease. Its Functional Fluidics collaboration, announced in July 2025, concerns red-cell health and quality assessment to support that development program. The latest award's acute-blood-loss objective should retain its own identity alongside this history.

Together, the relationships show how much responsibility sits between a cell-production milestone and clinical care. ARMI | BioFabUSA supports the manufacturing transition; DesiCorp works on preservation; Functional Fluidics contributes assessment expertise. Doug McConnell's team now has funding for the final preparatory work around its planned acute-blood-loss filing, carrying those separate bodies of work toward the first clinical questions its own manufactured cells will have to answer.